| __timestamp | Amphastar Pharmaceuticals, Inc. | BioMarin Pharmaceutical Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 40373000 | 302156000 |
| Thursday, January 1, 2015 | 46974000 | 402271000 |
| Friday, January 1, 2016 | 47298000 | 476593000 |
| Sunday, January 1, 2017 | 50918000 | 554336000 |
| Monday, January 1, 2018 | 58044000 | 604353000 |
| Tuesday, January 1, 2019 | 63109000 | 680924000 |
| Wednesday, January 1, 2020 | 65157000 | 737669000 |
| Friday, January 1, 2021 | 68920000 | 759375000 |
| Saturday, January 1, 2022 | 66592000 | 854009000 |
| Sunday, January 1, 2023 | 80393000 | 937300000 |
Unleashing the power of data
In the competitive landscape of pharmaceuticals, managing Selling, General, and Administrative (SG&A) expenses is crucial for operational efficiency. Over the past decade, BioMarin Pharmaceutical Inc. and Amphastar Pharmaceuticals, Inc. have demonstrated contrasting trends in their SG&A expenditures. From 2014 to 2023, BioMarin's SG&A expenses surged by approximately 210%, reflecting its aggressive expansion and investment in R&D. In contrast, Amphastar's expenses grew by about 99%, indicating a more conservative approach. Notably, BioMarin's expenses consistently outpaced Amphastar's, peaking at nearly 937 million in 2023, compared to Amphastar's 80 million. This disparity highlights BioMarin's larger scale and broader market reach. As the industry evolves, these trends offer insights into each company's strategic priorities and financial health, providing a window into their future growth trajectories.
Merck & Co., Inc. vs Amphastar Pharmaceuticals, Inc.: SG&A Expense Trends
Gilead Sciences, Inc. vs Amphastar Pharmaceuticals, Inc.: SG&A Expense Trends
Intra-Cellular Therapies, Inc. or Amphastar Pharmaceuticals, Inc.: Who Manages SG&A Costs Better?
Cost Management Insights: SG&A Expenses for BioMarin Pharmaceutical Inc. and Walgreens Boots Alliance, Inc.
Operational Costs Compared: SG&A Analysis of BioMarin Pharmaceutical Inc. and Alpine Immune Sciences, Inc.
Breaking Down SG&A Expenses: BioMarin Pharmaceutical Inc. vs TG Therapeutics, Inc.
SG&A Efficiency Analysis: Comparing BioMarin Pharmaceutical Inc. and Rhythm Pharmaceuticals, Inc.
TG Therapeutics, Inc. or Amphastar Pharmaceuticals, Inc.: Who Manages SG&A Costs Better?
Operational Costs Compared: SG&A Analysis of CRISPR Therapeutics AG and Amphastar Pharmaceuticals, Inc.
Who Optimizes SG&A Costs Better? Merus N.V. or Amphastar Pharmaceuticals, Inc.
Cost Management Insights: SG&A Expenses for Amphastar Pharmaceuticals, Inc. and Galapagos NV
Amphastar Pharmaceuticals, Inc. and Viridian Therapeutics, Inc.: SG&A Spending Patterns Compared